These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9248972)

  • 21. [Differential use of cephalosporins in treatment of upper and lower respiratory tract infections].
    Dvoretskiĭ LI; Omel'ianovskiĭ VV
    Antibiot Khimioter; 1998; 43(6):24-8. PubMed ID: 9644531
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections].
    Hernández-Martin J; Romá E; Salavert M; Doménech L; Poveda JL
    Rev Esp Quimioter; 2006 Sep; 19(3):231-46. PubMed ID: 17099791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid.
    Plouffe JF
    Clin Infect Dis; 2000 Sep; 31 Suppl 4():S144-9. PubMed ID: 11017864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The choice of antibacterial drugs.
    Med Lett Drugs Ther; 1999 Oct; 41(1064):95-104. PubMed ID: 10548955
    [No Abstract]   [Full Text] [Related]  

  • 26. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pharmacological evaluation of a modified cefotaxime bid regimen versus traditional tid in pediatric lower respiratory tract infections.
    Boccazzi A; Tonelli P; Bellosta C; Careddu P
    Diagn Microbiol Infect Dis; 1998 Dec; 32(4):265-72. PubMed ID: 9934543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of two populations of methicillin-resistant Staphylococcus aureus with distinct epidemiological, clinical and biological features, isolated from patients with community-acquired skin infections.
    Del Giudice P; Blanc V; Durupt F; Bes M; Martinez JP; Counillon E; Lina G; Vandenesch F; Etienne J
    Br J Dermatol; 2006 Jan; 154(1):118-24. PubMed ID: 16403104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antibiotic resistance and community-acquired infections].
    Manfredi R
    Recenti Prog Med; 2002 Mar; 93(3):149-56. PubMed ID: 11942163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cefotaxime, twenty years later. Observational study in critically ill patients].
    Alvarez-Lerma F; Palomar M; Olaechea P; Sierra R; Cerda E;
    Enferm Infecc Microbiol Clin; 2001 May; 19(5):211-8. PubMed ID: 11446909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefotaxime: United Kingdom clinical trial results in the treatment of severe infections.
    Bax RP; Young JP
    Curr Med Res Opin; 1981; 7(6):401-9. PubMed ID: 6263548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cefotaxime (klaforan) in modern therapy of bacterial infections].
    Khess R; Budanov SV
    Antibiot Khimioter; 1996 Mar; 41(3):44-56. PubMed ID: 8967803
    [No Abstract]   [Full Text] [Related]  

  • 36. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections.
    Bonsu BK; Shuler L; Sawicki L; Dorst P; Cohen DM
    Acad Emerg Med; 2006 Jan; 13(1):76-81. PubMed ID: 16365328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-hospital management of adults who have community-acquired pneumonia.
    Ortqvist A
    Semin Respir Infect; 1999 Jun; 14(2):135-50. PubMed ID: 10391408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibiotic therapy of bronchial infections. 2: Community acquired and nosocomial pneumonias].
    Buchenroth M
    MMW Fortschr Med; 1999 Dec; 141(49-50):48-50. PubMed ID: 10726149
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients.
    Roberts JA; Webb SA; Lipman J
    Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.